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Abstract
Introduction. The complement system is an essential part of the immune system of vertebrates. The central event of the
complement activation cascade is the sequential proteolytic activation of C3, which is associated with profound alterations in
the molecule’s structure and conformation and is responsible for triggering most of the biological effects of complement.
Material and methods. Here, we have studied the conformation of C3 fragments deposited onto an IgG-coated surface from
human serum during complement activation, using a set of unique monoclonal antibodies (mAbs) that are all speciﬁc for the
C3dg portion of bound iC3b.
Results. We were able to identify two conformational forms of target-bound iC3b: the ﬁrst recognized by mAb 7D18.1, and the
second by mAb 7D323.1. The ﬁrst species of iC3b bound recombinant complement receptor 1 (CR1), while the second bound
CR2. Since CR1 and CR2 are expressed by different subsets of leukocytes, this difference in receptor-binding capacity implies
that there is a biological difference between the two forms of surface-bound iC3b.
Conclusion. We propose that mAbs 7D18.1 and 7D323.1 can act as surrogate markers for CR1 and CR2, respectively, and that
they may be useful tools for studying the immune complexes that are generated in various autoimmune diseases.
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Introduction
The complement system is an essential part of the
innate immune system with the capacity to discrim-
inate between self and non-self. It is also an important
player in pathological processes, since it also recog-
nizes altered self in clinical settings such as reperfu-
sion injury and transplantation. The complement
system is a removal system, in that it eliminates
micro-organisms (bacteria, viruses, parasites),
immune complexes, and apoptotic cells from the
body. Complement factor C3 is the key component
in this system, and its cleavage to C3b by labile
composite enzymes (convertases) elicits inﬂammation
and cell lysis via target-bound C3 fragments (the
anaphylatoxins C3a and C5a) and the generation of
the membrane attack complex, C5b-9.
During its cleavage to C3b and iC3b, the
C3 molecule undergoes several profound structural
and conformational changes. These alterations in
structure and conformation have recently been eluci-
dated in a series of reports on the 3-D crystal structure
of the molecule (1–5). After cleavage of C3 by the
convertases, the so-called thiol ester domain (TED) is
totally dislocated and moved into a position that
allows covalent binding of the molecule to a target
surface. Digestion of C3b to iC3b by factor I affects
the molecule further by releasing the C3f fragment
and displacing the C3c domain from the TED.
Finally, factor I further cleaves iC3b, generating
the fragments C3dg (TED) and ﬂuid-phase C3c
(Figure 1).
The conformational changes that occur during the
activation of C3 are reﬂected in alterations in the
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C3 molecule. Immunization of rabbits and mice
with the native molecule as antigen tends to produce
antibodies directed toward both the ﬂuid-phase and
the target-bound molecules. In an attempt to generate
monoclonal antibodies (mAbs) that speciﬁcally rec-
ognize the bound conformations of C3 fragments, we
have produced mAbs against reduced polypeptide
chains of C3. A number of mAbs directed against
surface-bound C3 fragments (C3b, iC3b, C3dg) have
been generated (6), some of whose epitopes in the
C3 molecule have been mapped using cDNA-
expressed and synthesized peptides (7,8). Several of
these antibodies were directed against the N terminus
of the C3dg fragment and recognized the iC3b and
C3dg fragments (9). All of these mAbs, bound to
epitopes that are not totally exposed in the 3-D crystal
structure, indicate that there are still unidentiﬁed
conformational states that are associated with binding
of the molecule to target surfaces (1).
Binding of C3b to a target surface is associated with
exposure of epitopes in C3 that act as ligands for
complement receptors 1–4 (CR1–4). Two of these
receptors, CR1 (CD35) and CR2 (CD21), are short
consensus repeats (SCR) consisting of 30 (10,11) and
15 or 16 (due to alternative splicing) (12,13) residues,
respectively. CR1 is expressed on erythrocytes and
various phagocytes, whereas CR2 is speciﬁc for lym-
phocytes and follicular dendritic cells. In particular,
B-cells express a large number of CR2 molecules.
In the present paper, we have further characterized
the reactivity of four C3dg mAbs, 7D18.1, 7D84.1,
7D264.6, and 7D323.1, with regard to their binding
to different conformational states of surface-bound
C3b/iC3b that are associated with the binding of
complement receptors CR1 and CR2. A distinctive
association was found between the binding of the
mAbs and the receptors.
Material and methods
Serum preparations
Fresh, normal human blood was obtained from the
Blood Center of the University Hospital, Uppsala.
Normal human serum (NHS) was separated from
blood by centrifugation at 4000 g for 20 min at
+4C after clotting for 2–3 h at room temperature.
All analyses of complement in serum were performed
on stored, frozen material after rapid thawing at
37C. Freezing/refreezing and storage of material
were done at 70C. For some experiments, aliquots
of serum were heat-inactivated by incubation for
30 min at 56C.
Sources and preparation of puriﬁed proteins
Human IgG (gamma globulin) was obtained from
Pharmacia-Upjohn AB (Uppsala, Sweden), and
bovine serum albumin (BSA) (fraction V, RIA grade)
was purchased from the United States Biochemical
Corporation (Cleveland, OH, USA). Soluble com-
plement receptor 1 (sCR1) BRL 55730 was a kind gift
of Dr Henry Marsh (SmithKline Beecham Pharma-
ceuticals, King of Prussia, PA, USA). Culture super-
natants from Raji cells (Burkitt’s lymphoma), kindly
provided by Dr Sara Mangsbo, Rudbeck Laboratory,
were used as a source for CR2.
C3 and factor I were prepared from plasma accord-
ing to Hammer et al. (14) and Fearon (15), respec-
tively. Factor H was prepared from human serum
essentially according to Hammer et al., except that
the ﬁrst step consisted of a euglobulin precipitation
(16). C3b was produced by incubating C3 with tryp-
sin, followed by gel ﬁltration to remove C3a, and iC3b
was prepared by incubating C3b with factor I, using
factor H as co-factor.
Antibody preparations
Polyclonal (pAb) horseradish peroxidase-(HRP)-
conjugated anti-human C3c and C3d antibodies,
HRP-conjugated anti-mouse-Ig and non-conjugated
anti-BSA pAb, and mouse monoclonal anti-human
CR1 and anti-human CR2 antibodies were purchased
from Dako (Glostrup, Denmark).
Figure 1. Sequential digestion of C3, generating C3b, iC3b, C3c,
C3dg, and C3d. Activation of C3 leads to disruption of the thiol
ester (TE circular), which then establishes covalent bonds (TE
linear). The interchain disulﬁde bonds are indicated (S S).
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(mAbs) 7D18.1, 7D84.1, 7D264.6, and 7D323.1,
speciﬁc for epitopes in C3dg, were produced and
characterized as described previously (6,8).
Complement activation studies
Microtiter plates. Complement was activated in
the wells of 96-well polystyrene microtiter plates
(Maxisorp) (NUNC, Roskilde, Denmark) that had
been coated with IgG as described below. The con-
formationofthedepositedC3fragmentswasvisualized
by ELISA using polyclonal (pAb) and monoclonal
(mAb) anti-C3 antibodies. Each experiment was
repeated ﬁve to ten times with similar results. Further-
more, analysis of the deposited C3 fragments was
performed using Western blot analysis.
Diluents for functional studies and ELISAs. Reagents
that were tested functionally were diluted in veronal-
buffered saline (VBS) consisting of 5 mM veronal,
pH 7.5, with NaCl (145 mM), Ca
2+ (0.15 mM), and
Mg
2+ (0.5 mM). Some experiments were per-
formed in VBS supplemented with 0.1% (w/v) gelatin
(GVB). Phosphate-buffered saline (PBS) containing
0.05% (v/v) Tween 20 and 0.02% (v/v) Antifoam
(Dispensor-Aspirator, Pharmacia-Upjohn, Uppsala,
Sweden) was used as the washing ﬂuid. Antibody
dilutions were carried out in washing ﬂuid containing
0.1% (w/v) gelatin. Undesired protein adsorption to
polystyrene plates was prevented by incubating the
microtiter wells with 1% (w/v) gelatin in PBS at
room temperature for 30 min.
Complement-activating target surfaces. Plates were incu-
bated for 1 h at 37C with 0.2 mL PBS/well of
monomeric human IgG at 80 mg/mL, washed 3
with PBS, blocked 30 min at room temperature
with 0.3 mL 1% gelatin, and rinsed with VBS. The
IgG-coated plates were used immediately or after
storage at 70C, with 0.3 mL VBS being added
per well.
Complement activation. Human serum was diluted in
VBS from 100% in 3-fold steps and incubated in pre-
warmed IgG-coated microtiter wells for 2.5 to
120 min, at 37C as described elsewhere (17). The
reaction was stopped by washing with washing
ﬂuid containing 10 mM EDTA. The bound C3
fragments were detected using rabbit pAbs anti-
C3c and anti-C3d, as well as a panel of four mAbs
against epitopes in the C3dg region of C3. The
bound primary antibodies were detected using
HRP-conjugated anti-rabbit immunoglobulins (pAbs)
or HRP-conjugated anti-mouse immunoglobulins
(mAbs).
Binding of complement receptors (CR) 1 and 2 to depos-
ited C3 fragments. The ability of the deposited C3
fragments to act as ligands for CR1 and CR2 was
investigated by adding recombinant sCR1 or Raji
supernatants containing soluble CR2 into microtiter
wells in which complement activation had been
achieved as described above. After incubation at
37C for 30 min, mAbs recognizing CR1 or CR2
were used for detection, in conjunction with HRP-
conjugated anti-mouse immunoglobulins.
Factor I-mediated cleavage of bound C3 fragments with
CR1 as co-factor. In order to promote the digestion to
iC3b or C3dg of the C3 fragments deposited by
complement activation in the IgG-coated microtiter
wells, separate experiments were performed in which
complement activation was performed as described
above. Thereafter, sCR1 and heat-inactivated human
serum (or buffer as negative control) were added and
incubated at 37C for 30 min to enable the factor I
in serum to digest the deposited C3b, with sCR1 as
co-factor. Subsequently, Raji supernatants containing
soluble CR2 were added to some of the microtiter
wells. Finally, bound C3 fragments and CR1 and
CR2 were detected as described above.
Western blot analysis of bound C3 fragments
Human serum (undiluted) was incubated in IgG-
coated microtiter wells as described above for up to
60 min. After washing, 25 mL 0.1 M methylamine in
0.1 M glycine-NaOH buffer, pH 8, was added to
each well and incubated at room temperature with
agitation for 10 min. Thereafter, 25 mL SDS-
electrophoresis buffer (12 mM Tris, 0.4% SDS, pH
6.8)wasaddedtoeachwellofthemicrotiterplate,which
wasthenheatedto85Cfor5min.Aftertheincubation,
thesupernatantswereloadedonto10%SDSpolyacryle
amidegelelectrophoresis(SDS-PAGE)gels.Afterelec-
trophoretic separation, the proteins were transferred to
aP V D FI m m u n - B l o tm e m b r a n e( B i o R a d ,H e r c u l e s ,
CA, USA), and the membrane was blocked in 1%
bovineserumalbumindiluted inPBS-Tween.Proteins
were detected with biotinylated pAb anti-C3d and
anti-C3c, or mAb 7D264.6, followed by streptavidin-
HRP and staining with 3,3¢-diaminobenzidine tetrahy-
drochloride (Sigma, Steinheim, Germany) dissolved in
PBS (1 mg/mL plus 0.5 mLH 2O2/mL). Puriﬁed C3,
C3b, and iC3b were used as controls.
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Epitope expression of human C3 bound to adsorbed
human IgG
Incubation of serum in wells coated with adsorbed
IgG for 60 min at 37C induced complement activa-
tion, leading to the deposition of C3 fragments on
the microtiter plate surface; the highest level of bind-
ing was seen with undiluted serum, as detected by
pAbs anti-C3c and anti-C3d and mAb 7D323.1
(Figure 2A). In contrast, mAb 7D18.1 showed the
lowest level of binding at the highest serum concen-
tration. The binding proﬁles of these two mAbs,
together with those of mAbs 7D84.1 and 7D264.6,
were further examined after 120 min of complement
activation. Under these conditions, binding of mAb
7D323.1 was further increased, again with the highest
level achieved with undiluted serum; the other mAbs
showed similar binding proﬁles, peaking at a serum
concentration of ~3% (Figure 2B). Data presented in
each panel in Figures 2–4 are from one representative
experiment out of ﬁve to ten experiments which were
performed with similar results.
Receptor ligand function of human C3 bound to adsorbed
human IgG
The C3 fragments deposited on adsorbed IgG as a
result of complement activation of serially diluted
serum were able to act as a ligand for exogenously
added CR1 (Figure 3A). The CR1-binding epitopes
were already exposed on C3 after 2.5 min of
incubation, with maximal expression at high serum
concentration (30%). After prolonged incubation
(60 min), maximal binding of CR1 was seen at a
lower serum concentration (3%). The binding proﬁle
of CR1 closely resembled that of mAb 7D18.1
(Figure 3B). Surface-bound C3 fragments also bound
CR2, but this binding was seen only on surfaces that
had been in contact with high concentrations of
serum, at both 2.5 and 60 min (Figure 3C). The
binding of mAb 323.1 mirrored that of CR2
(Figure 3D).
Ligand binding of factor I-digested surface-bound
C3 fragments
C3 fragments were deposited on surface-bound
IgG from serially diluted serum. After removal of
the serum, CR1 was added together with heat-
inactivated human serum as a source of factor I to
enable the digestion of the deposited C3 fragments to
yield iC3b and C3dg. CR1 did not bind to the
surface-bound digested C3 fragments, but binding
was seen in the wells that had been incubated with
CR1 and the buffer control (Figure 4A). Since there
was a surplus of CR1 after addition, it was also
detected at high serum concentration. After digestion,
the binding proﬁle of mAb 7D18.1 shifted from its
previous maximum at 3% serum to a peak at 30%
serum, suggesting a lower density of binding epitopes
(Figure 4B). In contrast, factor I-mediated cleavage of
the deposited C3 fragments did not affect the binding
of CR2 (Figure 4C) or mAb 7D323.1 (Figure 4D).
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Figure 2. Epitope expression of human C3 bound to adsorbed human IgG. Human serum was added in 3-fold serial dilution from 100% and
incubated at 37C for 60 min (panel A) or 120 min (panel B). Bound C3 was detected using pAbs anti-C3d (ﬁlled triangles) and anti-C3c
(open triangles), and mAbs 7D323.1 (squares), 7D18.1 (circles), 7D264.6 (open diamonds), and 7D84.1 (ﬁlled diamonds).
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The composition of the deposited C3 fragments was
further investigated by Western blot analysis. Undi-
luted serum was incubated on IgG-coated ELISA
plates for up to 60 min. After washing, the bound
proteins were eluted with methylamine, and the
eluted C3 fragments were visualized by Western
blot analysis using pAbs against C3d (molecular
weight » 35 kDa) and mAb 7D264.6 against an
epitope in C3dg, both of which also detected the
corresponding epitopes in the 110-kDa a-chain of
C3 and the 100-kDa a¢-chain of C3b; we also used
pAbs against C3c, which detected the 75-kDa
b-chain and the 45-kDa polypeptide chain of C3c,
including the corresponding epitopes in the 110-kDa
a-chain of C3, the 100-kDa a¢-chain of C3b, and the
67-kDa fragment of iC3b (Figure 5).
The staining of the anti-C3d pAbs in the controls
followed the expected pattern. In the eluted samples,
we saw weak staining of a band of 67 kDa (i.e. the
67-kDa band of iC3b), but no band of 40 kDa (i.e.
free C3dg). However, the most abundant staining
with anti-C3d pAbs was of high molecular weight
material (>150 kDa) in the eluates, suggesting that
most of the C3 fragments with exposed epitopes
recognized by the anti-C3d pAbs were covalently
bound to other proteins, producing higher molecular
weight eluates. The pattern did not alter during
incubation for up to 60 min (Figure 6A). Staining
with mAb 7D264.6 revealed the presence of the
67-kDa fragment of iC3b at all time points, with no
further digestion to C3dg over time (Figure 6B).
There was no indication of heterogeneity in the size
of this fragment. Staining with pAb anti-C3c con-
ﬁrmed the presence of iC3b by detecting the 75-kDa
b-chain at all time points, as well as the 45-kDa
polypeptide chain present in C3c and iC3b
(Figure 6C).
Discussion
In the present work, we have demonstrated a strict
relationship between the iC3b binding patterns of
7D18.1 and 7D323.1 and complement receptors
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Figure 3. Binding of CR1 (panel A), anti-C3 mAb 7D18.1 (panel B), CR2 (panel C), and anti-C3 mAb 7D323.1 (panel D) to human
C3 bound to adsorbed human IgG. Human serum (in 3-fold serial dilution from 100%) was added and incubated at 37C for 2.5 min (dashed
lines) or 60 min (solid lines).
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Figure 4. Binding of CR1 (panel A) and anti-C3 mAb 7D18.1 (panel B) and of CR2 (panel C) and anti-C3 mAb 7D323.1 (panel D) to human
C3 fragments bound to adsorbed human IgG. The coated surfaces were incubated ﬁrst with human serum in 3-fold serial dilution from 100%
at 37C for 60 min. After washing, heat-inactivated human serum was then added, together with buffer (solid lines) or soluble CR1 to enable
digestion of deposited iC3b to C3dg (dashed lines).
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Figure 5. Electrophoretic pattern of polypeptide chains from the various C3 fragments. The molecular weights (Mw) of the standards are
indicated.
Neo-epitopes in surface-bound human iC3b 31CR1 and CR2, respectively. The two antibodies were
able to distinguish between two forms of iC3b, which
are produced not by structural differences but appar-
ently as a result of conformational changes in the
molecule, indicating that the difference in binding
of the receptors is related to a conformational change.
Monoclonal antibodies 7D18.1, 7D84.1, 7D264.6,
and 7D323.1 all bound preferentially to bound
C3 fragments, but the binding of 7D323.1 was less
strictly limited to bound iC3b, since it also recognized
the molecule in the ﬂuid phase. The epitopes of all
four antibodies are found close to each other in the N
terminus of C3dg and have been pinned down to
single amino acid residues (8,9,18). All four mAbs
bind to C3 (929–932), but 7D264.6 also recognizes
C3 (929–936), and 7D323.1 binds to rabbit C3,
which has a slightly different sequence in this region:
Hu929R versus Ra929N and (18) Hu932R versus
Ra932Q, respectively (19,20). Thus, the location of
the epitopes differs by only a few amino acid residues.
All the anti-C3dg mAbs were tested for binding to
C3 fragments that had been generated and bound to
IgG adsorbed in microtiter wells after incubation with
NHS for 60 and 120 min, and their binding was
compared with that of pAbs anti-C3c and anti-C3d,
which acted as internal standards for the binding of
antibodies to the bound C3 fragments. These studies
showed that 7D323.1 bound to C3 fragments at both
time points and at all concentrations of NHS, while
7D18.1 and the other two mAbs bound less intensely
at the higher concentrations of NHS.
When the binding of mAbs was compared with
that of ﬂuid-phase recombinant CR1 (CD35) and
CR2 (CD21), a close relationship was seen between
the binding of the receptors and the mAbs. CR1
bound to a maximum level at a fairly low concentra-
tion of NHS, and its level of binding decreased at
higher concentrations. This binding pattern was sim-
ilar to that of 7D18.1, 7D84.1, and 7D264.6, as
exempliﬁed by the binding of 7D18.1. On the other
hand, the binding of CR2 increased with increasing
concentration of NHS. This reactivity was mirrored
by the binding of 7D323.1.
There are two possible explanations for this pattern
of reactivity: There may be structural differences
between the two forms of iC3b, or there may be
conformational changes that are associated with the
two different forms of iC3b. In the transformation of
C3b to iC3b, factor I cleaves the a-chain of C3b at
two sites, ﬁnally releasing the C3f fragment. Theo-
retically, these cleavages can occur in a stepwise
manner to generate two forms of iC3b, which could
therefore differ in their reactivity with the receptors
and mAbs. In order to rule out this possibility, we
analyzed the C3 fragments by Western blotting, which
revealed that the bound fragments were in the iC3b
form and there were no differences associated with the
various concentrations that were used, or with the
length of the incubation with the NHS. No differences
were found in the 45-kDa polypeptide of C3c or the
C3dg fragment, which are the polypeptides which
would be affected if a stepwise generation of iC3b
were to occur. A further indication that the surfaces
were coated with iC3b was the fact that when the
bound iC3b was cleaved to generate C3dg as a
result of incubation of the microtiter plates with
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Figure 6. Western blot analysis of C3 fragments eluted from an
IgG-coated surface exposed to undiluted human serum for 0, 5, 10,
20, or 60 min, detected using: pAb anti-C3d (panel A), mAb anti-
C3 7D264.6 (panel B), and pAb anti-C3c (panel C). Reference
preparations of C3, C3b, and iC3b were also analyzed, and the
molecular weights (Mw) of the standards are indicated.
32 U. R. Nilsson et al.heat-inactivated NHS and soluble CR1, the binding
of CR1 to the surface was lost. This was a ﬁnding that
is in agreement with the loss of afﬁnity of the receptor
for C3 fragments in the case of C3dg. The reactivity
with CR2 remained, as did the binding of the mAbs,
since their epitopes are present in the N-terminal
portion of the C3dg molecule. Taken together, these
results suggest that the differences in binding of the
mAbs and complement receptors reﬂect conforma-
tional changes in the molecule, and not structural
differences.
In summary, this study has identiﬁed two forms of
iC3b that have distinctive binding reactivities with the
complement receptors CR1 and CR2. These forms of
iC3b were speciﬁcally detected by the mAbs 7D18.1
and 7D323.1, respectively. The reactivity of these
mAbs is potentially of great interest, since the binding
of iC3b to CR1 and CR2 generates totally different
biological responses in the two cases. The mAbs can
therefore be used as reagents to identify the different
conformational and functional forms of iC3b bound
to various immune complexes (21). Since immune
complexes are found in many autoimmune diseases,
such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis, assays employing these anti-
bodies would add a new dimension to the analysis
of immune complexes in patients with these types of
disease.
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